155 related articles for article (PubMed ID: 19637944)
1. Assessment of an alternative meropenem dosing strategy compared with imipenem-cilastatin or traditional meropenem dosing after cefepime failure or intolerance in adults with neutropenic fever.
Arnold HM; McKinnon PS; Augustin KM; Hladnik LM; Casabar E; Reichley RM; Dubberke ER; Westervelt P; Ritchie DJ
Pharmacotherapy; 2009 Aug; 29(8):914-23. PubMed ID: 19637944
[TBL] [Abstract][Full Text] [Related]
2. Cefozopran, meropenem, or imipenem-cilastatin compared with cefepime as empirical therapy in febrile neutropenic adult patients: A multicenter prospective randomized trial.
Nakane T; Tamura K; Hino M; Tamaki T; Yoshida I; Fukushima T; Tatsumi Y; Nakagawa Y; Hatanaka K; Takahashi T; Akiyama N; Tanimoto M; Ohyashiki K; Urabe A; Masaoka T; Kanamaru A;
J Infect Chemother; 2015 Jan; 21(1):16-22. PubMed ID: 25239059
[TBL] [Abstract][Full Text] [Related]
3. A prospective, randomized study comparing cefepime and imipenem-cilastatin in the empirical treatment of febrile neutropenia in patients treated for haematological malignancies.
Cherif H; Björkholm M; Engervall P; Johansson P; Ljungman P; Hast R; Kalin M
Scand J Infect Dis; 2004; 36(8):593-600. PubMed ID: 15370671
[TBL] [Abstract][Full Text] [Related]
4. Empirical monotherapy with meropenem versus imipenem/cilastatin for febrile episodes in neutropenic patients.
Shah PM; Heller A; Fuhr HG; Walther F; Halir S; Schaumann R; Böhme A; Jung B; Köhler A; Lips-Schulte C; Stille W
Infection; 1996; 24(6):480-4. PubMed ID: 9007599
[TBL] [Abstract][Full Text] [Related]
5. Cefepime versus imipenem-cilastatin as empirical monotherapy in 400 febrile patients with short duration neutropenia. CEMIC (Study Group of Infectious Diseases in Cancer).
Biron P; Fuhrmann C; Cure H; Viens P; Lefebvre D; Thyss A; Viot M; Soler-Michel P; Rollin C; Grès JJ
J Antimicrob Chemother; 1998 Oct; 42(4):511-8. PubMed ID: 9818751
[TBL] [Abstract][Full Text] [Related]
6. Adverse events associated with meropenem versus imipenem/cilastatin therapy in a large retrospective cohort of hospitalized infants.
Hornik CP; Herring AH; Benjamin DK; Capparelli EV; Kearns GL; van den Anker J; Cohen-Wolkowiez M; Clark RH; Smith PB;
Pediatr Infect Dis J; 2013 Jul; 32(7):748-53. PubMed ID: 23838776
[TBL] [Abstract][Full Text] [Related]
7. The cost-effectiveness of empirical antibiotic treatments for high-risk febrile neutropenic patients: A decision analytic model.
Tori K; Tansarli GS; Parente DM; Kalligeros M; Ziakas PD; Mylonakis E
Medicine (Baltimore); 2020 May; 99(20):e20022. PubMed ID: 32443305
[TBL] [Abstract][Full Text] [Related]
8. Impact of the introduction of real-time therapeutic drug monitoring on empirical doses of carbapenems in critically ill burn patients.
Fournier A; Eggimann P; Pagani JL; Revelly JP; Decosterd LA; Marchetti O; Pannatier A; Voirol P; Que YA
Burns; 2015 Aug; 41(5):956-68. PubMed ID: 25678084
[TBL] [Abstract][Full Text] [Related]
9. Treatment of febrile neutropenic patients with cancer who require hospitalization: a prospective randomized study comparing imipenem and cefepime.
Raad II; Escalante C; Hachem RY; Hanna HA; Husni R; Afif C; Boktour MR; Whimbey EE; Kontoyiannis D; Jacobson K; Kantarjian H; Levett LM; Rolston KV
Cancer; 2003 Sep; 98(5):1039-47. PubMed ID: 12942573
[TBL] [Abstract][Full Text] [Related]
10. Comparison of 30-min and 3-h infusion regimens for imipenem/cilastatin and for meropenem evaluated by Monte Carlo simulation.
Lee LS; Kinzig-Schippers M; Nafziger AN; Ma L; Sörgel F; Jones RN; Drusano GL; Bertino JS
Diagn Microbiol Infect Dis; 2010 Nov; 68(3):251-8. PubMed ID: 20851549
[TBL] [Abstract][Full Text] [Related]
11. Retrospective evaluation of piperacillin-tazobactam, imipenem-cilastatin and meropenem used on surgical floors at a tertiary care hospital in Saudi Arabia.
Youssif E; Aseeri M; Khoshhal S
J Infect Public Health; 2018; 11(4):486-490. PubMed ID: 29153444
[TBL] [Abstract][Full Text] [Related]
12. Comparison of cefoperazone and mezlocillin with imipenem as empiric therapy in febrile neutropenic cancer patients.
Mortimer J; Miller S; Black D; Kwok K; Kirby WM
Am J Med; 1988 Jul; 85(1A):17-20. PubMed ID: 3400679
[TBL] [Abstract][Full Text] [Related]
13. Meropenem versus imipenem/cilastatin in the treatment of hospitalized patients with skin and soft tissue infections.
Nichols RL; Smith JW; Geckler RW; Wilson SE
South Med J; 1995 Apr; 88(4):397-404. PubMed ID: 7716590
[TBL] [Abstract][Full Text] [Related]
14. Imipenem/cilastatin (1.5 g daily) versus meropenem (3.0 g daily) in patients with intra-abdominal infections: results of a prospective, randomized, multicentre trial.
Basoli A; Meli EZ; Mazzocchi P; Speranza V
Scand J Infect Dis; 1997; 29(5):503-8. PubMed ID: 9435041
[TBL] [Abstract][Full Text] [Related]
15. A Retrospective Study on the Incidence of Seizures among Neurosurgical Patients Who Treated with Imipenem/Cilastatin or Meropenem.
Wu Y; Chen K; Shi Z; Wang Q
Curr Pharm Biotechnol; 2014; 15(8):685-90. PubMed ID: 25051950
[TBL] [Abstract][Full Text] [Related]
16. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of meropenem compared to imipenem-cilastatin in young, healthy males.
Nilsson-Ehle I; Hutchison M; Haworth SJ; Norrby SR
Eur J Clin Microbiol Infect Dis; 1991 Feb; 10(2):85-8. PubMed ID: 1864280
[TBL] [Abstract][Full Text] [Related]
18. Meropenem versus imipenem/cilastatin in the treatment of intra-abdominal infections.
Brismar B; Malmborg AS; Tunevall G; Lindgren V; Bergman L; Mentzing LO; Nyström PO; Anséhn S; Bäckstrand B; Skau T
J Antimicrob Chemother; 1995 Jan; 35(1):139-48. PubMed ID: 7768761
[TBL] [Abstract][Full Text] [Related]
19. [Meropenem (Merrem) vs imipenem/cilastatin in hospital treatment of intra-abdominal infections. A multicenter study].
Tonelli F
Minerva Chir; 1997 Mar; 52(3):317-26. PubMed ID: 9148225
[TBL] [Abstract][Full Text] [Related]
20. Antibiotic rotation for febrile neutropenic patients with hematological malignancies: clinical significance of antibiotic heterogeneity.
Chong Y; Shimoda S; Yakushiji H; Ito Y; Miyamoto T; Kamimura T; Shimono N; Akashi K
PLoS One; 2013; 8(1):e54190. PubMed ID: 23372683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
